株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

創傷:パイプライン分析

Wounds - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 255970
出版日 ページ情報 英文 224 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
創傷:パイプライン分析 Wounds - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 224 Pages
概要

創傷は、手術、怪我、化学薬品、熱や冷気への接触、摩擦、圧力、あるいは下肢潰瘍や癌など疾患の影響で、皮膚と皮下組織が傷つくことで起こる皮膚の保護機能の損傷(上皮細胞の連続性の損壊)であり、皮下接合組織(筋肉、骨、神経)の損傷を含む場合と含まない場合があります。傷の周辺が発赤あるいは赤い線状になり、幹部の腫れ、膿状の液体の分泌、悪臭、悪寒、発熱などの症状があります。抗生剤の利用などの治療法があります。

当レポートでは、世界における創傷治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

創傷の概要

治療薬の開発

  • 創傷向けパイプライン製品:概要
  • 創傷向けパイプライン製品:比較分析

創傷:開発中の治療薬:企業別

創傷:開発中の治療薬:大学・研究機関別

創傷:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

創傷:開発中の製品:企業別

創傷:開発中の製品:大学・研究機関別

創傷:治療薬開発に従事している企業

  • Cardium Therapeutics, Inc.
  • Smith & Nephew Plc
  • Sanofi
  • Biotec Pharmacon ASA
  • Kuros Biosurgery AG
  • Pharming Group N.V.
  • Stratatech Corporation
  • Photopharmica Limited
  • Tissue Repair Company
  • Nanotherapeutics, Inc.
  • Octapharma AG
  • Apricus Biosciences, Inc.
  • Bio3 Research S.r.l
  • NeoStem, Inc.
  • HanAll Biopharma Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.
  • CytoTools AG
  • CYATHUS EXQUIRERE PharmaforschungsGmbH
  • MetrioPharm AG
  • Dongkook Pharmaceutical Co., Ltd.
  • Juventas Therapeutics, Inc.
  • Omnio Healer AB
  • ConjuGon, Inc.
  • Garnet BioTherapeutics
  • Gene Signal International SA
  • AndroScience Corporation
  • GliaMed, Inc.
  • Omeros Corporation
  • NanoBio Corporation
  • FirstString Research, Inc.
  • Molecular Design International, Inc.
  • Sirnaomics, Inc.
  • SunTen Phytotech Co., Ltd.
  • miRagen Therapeutics, Inc.
  • Pacific Northwest Biotechnology, LLC
  • Beech Tree Labs, Inc.
  • Mirrx Therapeutics A/S
  • EyeGene, Inc.
  • Neumedicines Inc.
  • AlgiPharma AS
  • SomaGenics Inc.
  • Advancell
  • Birken AG
  • Provasculon, Inc.
  • Pergamum AB
  • Microbion Corporation
  • Escape Therapeutics, Inc.
  • Kasiak Research Pvt. Ltd.
  • Regenics AS
  • vida therapeutics inc.
  • Hemostemix Ltd

創傷:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • MB-11316
  • ドキシサイクリン
  • GAM-501
  • DermaPro CL-05
  • GBT-009
  • HP-802247
  • StrataGraft皮膚組織
  • KUR-212
  • PPA-904
  • Granexin
  • CSTC-1
  • Evitar
  • JVS-100
  • 創傷治療のための間葉細胞
  • ビスマスエタンジチオール
  • MALP-2
  • KUR-213
  • GM-1485
  • CTR-2
  • cobiprostone
  • アルプロスタジル
  • ASCJ-9
  • MDI-301
  • GS-156
  • 可溶性ベータグルカン
  • MGN-4220
  • STP-705
  • BTL-slo
  • NB-201
  • 炎症、虚血症、創傷治癒のためのVEカドヘリン阻害RNAiオリゴヌクレオチド
  • NMIL-121
  • Vasculotide
  • AKB-4924
  • ニューロテンシン
  • C-31510
  • MP-1031
  • 皮膚病・感染症向けペプチド
  • CM-101
  • 慢性創傷・皮膚硬化症のための幹細胞治療
  • ANs-31
  • HL-156Fib
  • AlloGraf
  • GN-4474
  • HDFx
  • 創傷向けc-Met拮抗薬
  • EG-Decorin
  • 慢性傷感染向けビスマスチオール化合物
  • 創傷向け幹細胞治療
  • 急性創傷治療のための小分子
  • AG-30/5C
  • 組み換えプラスミノーゲン
  • Vernex
  • V-2248
  • 移動刺激因子
  • STD-06
  • 感染症、ショック、呼吸器障害のためのSEB・TSST-1阻害たんぱく質
  • NL-005
  • hVGF
  • PGF
  • 脱毛症、肺線維症、皮膚病向け成長因子ベータ受容体変形小分子アンタゴニスト
  • Nu-2
  • PRF-65339
  • A3-APO
  • BCI
  • コーディン
  • ヒト可溶性CD-146
  • フェニトイン
  • 塩化ピルビニウム
  • Cyathus-1102-B
  • 創傷治癒のための幹細胞治療
  • DNAプロドラッグプログラム
  • 炎症、やけど、創傷のためのモノクローナル抗体ゲル
  • 創傷・潰瘍のCA5-HIF遺伝子治療
  • 創傷治癒のための11s-HSD1阻害薬
  • 皮膚創傷のための脂肪幹細胞治療
  • 糖尿病性慢性皮膚創傷のための自己由来脂肪幹細胞治療
  • NVN-4428
  • I型組み換えヒトコラーゲン
  • 創傷・火傷のためのOligoG
  • 創傷治癒・新しい毛嚢形成のためのLGR6標的小分子
  • アジアチコシド誘導体
  • GP-505
  • 皮膚疾患・感染症向け酵素
  • 創傷の細胞治療
  • 線維芽細胞増殖因子結合体
  • PXL-181
  • 創傷治癒のためのRNAiオリゴヌクレオチド
  • 創傷治癒プログラム
  • 無糖線維芽細胞増殖因子
  • 中毒、代謝性疾患、筋骨格系疾患のためのNOシンターゼ阻害小分子
  • BCP-01
  • Refaheal
  • ヒト成長因子
  • 組換えプラスミノーゲン
  • XEN-103
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8900IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 56, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wounds Overview
  • Therapeutics Development
    • Pipeline Products for Wounds - Overview
    • Pipeline Products for Wounds - Comparative Analysis
  • Wounds - Therapeutics under Development by Companies
  • Wounds - Therapeutics under Investigation by Universities/Institutes
  • Wounds - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Wounds - Products under Development by Companies
  • Wounds - Products under Investigation by Universities/Institutes
  • Wounds - Companies Involved in Therapeutics Development
    • Aerpio Therapeutics Inc
    • AlgiPharma AS
    • AmpliPhi Biosciences Corp
    • AndroScience Corp
    • Aridis Pharmaceuticals LLC
    • Beech Tree Labs Inc
    • Bio3 Research Srl
    • Biotec Pharmacon ASA
    • Blueberry Therapeutics Ltd
    • Cellphire Inc
    • CorMedix Inc
    • Dermala Inc
    • Destiny Pharma Ltd
    • Escape Therapeutics Inc
    • EyeGene Inc
    • FibroGen Inc
    • GangaGen Inc
    • Gene Signal International SA
    • GlaxoSmithKline Plc
    • IC-MedTech Inc
    • Living Cell Technologies Ltd
    • Madam Therapeutics BV
    • miRagen Therapeutics Inc
    • NatureWise Biotech & Medicals Corp
    • Novan Inc
    • NuvOx Pharma LLC
    • Octapharma AG
    • Omeros Corp
    • Osiris Therapeutics Inc
    • Pacific Northwest Biotechnology LLC
    • Pharmaxis Ltd
    • ProMetic Life Sciences Inc
    • RiverTown Therapeutics Inc
    • RMB-Research GmbH
    • RXi Pharmaceuticals Corp
    • Sinclair Pharma Plc
    • SomaGenics Inc
    • Stratatech Corp
    • TGV-Laboratories
    • Thesan Pharmaceuticals Inc
    • Topadur Pharma AG
    • Trophogen Inc
    • Tumorend LLC
    • VBS Pharmaceuticals
    • viDA Therapeutics Inc
  • Wounds - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
    • A-3APO - Drug Profile
    • ABSA-01 - Drug Profile
    • AKB-4924 - Drug Profile
    • ALLO-ASC - Drug Profile
    • AlloGraf - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile
    • APO-1 - Drug Profile
    • APO-2 - Drug Profile
    • AR-101 - Drug Profile
    • Arginine Butyrate - Drug Profile
    • ARN-077 - Drug Profile
    • ASCJ-9 - Drug Profile
    • B-244 - Drug Profile
    • BB-1000 - Drug Profile
    • BDM-I - Drug Profile
    • BTL-slo - Drug Profile
    • CAR Peptide - Drug Profile
    • Cell Therapy for Chronic Wounds - Drug Profile
    • Cell Therapy for Dermatology and Immunology - Drug Profile
    • Cell Therapy for Wounds - Drug Profile
    • CM-101 - Drug Profile
    • CRMD-004 - Drug Profile
    • CTR-2 - Drug Profile
    • daprodustat - Drug Profile
    • DB-2121 - Drug Profile
    • Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile
    • Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile
    • Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
    • EGS-001 - Drug Profile
    • FG-6874 - Drug Profile
    • G-3KL - Drug Profile
    • Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
    • Gene Therapy to Activate HSP60 for Wounds - Drug Profile
    • GS-156 - Drug Profile
    • Human Growth Factor - Drug Profile
    • hVGF - Drug Profile
    • JM-2 - Drug Profile
    • KL-7016 - Drug Profile
    • LWnt-3a - Drug Profile
    • MG-53 - Drug Profile
    • MMP-26051 - Drug Profile
    • MMP-26052 - Drug Profile
    • molgramostim - Drug Profile
    • Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
    • MRG-110 - Drug Profile
    • Mul-1867 - Drug Profile
    • NBM-67 - Drug Profile
    • ND-336 - Drug Profile
    • NTCELL - Drug Profile
    • Oligomer G for Wounds And Burns - Drug Profile
    • OTI-1011 - Drug Profile
    • OTI-1502 - Drug Profile
    • P-128 - Drug Profile
    • P-148 - Drug Profile
    • Panaecin - Drug Profile
    • perflenapent for wound healing - Drug Profile
    • Perlecan - Drug Profile
    • PGF - Drug Profile
    • plasminogen (recombinant) - Drug Profile
    • Polysaccharide for Wounds and Scars - Drug Profile
    • Protein for Diabetic Wound Healing - Drug Profile
    • Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile
    • Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile
    • Protein to Activate FGF2 for Wound Healing - Drug Profile
    • Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
    • PXS-4820 - Drug Profile
    • Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
    • Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile
    • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
    • Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile
    • Recombinant Protein to Inhibit SEB and TSST-1 for Pulmonary Infections, Bacterial Infections, Toxic Shock and Wounds - Drug Profile
    • Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
    • RT-1740 - Drug Profile
    • SG-404 - Drug Profile
    • silver sulfadiazine - Drug Profile
    • Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile
    • Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile
    • Small Molecule to Target LGR6 for Dermatology - Drug Profile
    • Small Molecules for Staphylococcal Infections and Wounds - Drug Profile
    • Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile
    • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    • Soluble Beta Glucan - Drug Profile
    • Statmicoll - Drug Profile
    • Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile
    • Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
    • Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile
    • Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
    • Thrombosomes - Drug Profile
    • Tolecine - Drug Profile
    • TOPN-53 - Drug Profile
    • TRBN-0224 - Drug Profile
    • TWB-103 - Drug Profile
    • V-2248 - Drug Profile
    • VTI-3000 Series - Drug Profile
    • WH-1 - Drug Profile
    • XF-70 - Drug Profile
  • Wounds - Dormant Projects
  • Wounds - Discontinued Products
  • Wounds - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wounds, H2 2016
  • Number of Products under Development for Wounds - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Wounds - Pipeline by Aerpio Therapeutics Inc, H2 2016
  • Wounds - Pipeline by AlgiPharma AS, H2 2016
  • Wounds - Pipeline by AmpliPhi Biosciences Corp, H2 2016
  • Wounds - Pipeline by AndroScience Corp, H2 2016
  • Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Wounds - Pipeline by Beech Tree Labs Inc, H2 2016
  • Wounds - Pipeline by Bio3 Research Srl, H2 2016
  • Wounds - Pipeline by Biotec Pharmacon ASA, H2 2016
  • Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2016
  • Wounds - Pipeline by Cellphire Inc, H2 2016
  • Wounds - Pipeline by CorMedix Inc, H2 2016
  • Wounds - Pipeline by Dermala Inc, H2 2016
  • Wounds - Pipeline by Destiny Pharma Ltd, H2 2016
  • Wounds - Pipeline by Escape Therapeutics Inc, H2 2016
  • Wounds - Pipeline by EyeGene Inc, H2 2016
  • Wounds - Pipeline by FibroGen Inc, H2 2016
  • Wounds - Pipeline by GangaGen Inc, H2 2016
  • Wounds - Pipeline by Gene Signal International SA, H2 2016
  • Wounds - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Wounds - Pipeline by IC-MedTech Inc, H2 2016
  • Wounds - Pipeline by Living Cell Technologies Ltd, H2 2016
  • Wounds - Pipeline by Madam Therapeutics BV, H2 2016
  • Wounds - Pipeline by miRagen Therapeutics Inc, H2 2016
  • Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016
  • Wounds - Pipeline by Novan Inc, H2 2016
  • Wounds - Pipeline by NuvOx Pharma LLC, H2 2016
  • Wounds - Pipeline by Octapharma AG, H2 2016
  • Wounds - Pipeline by Omeros Corp, H2 2016
  • Wounds - Pipeline by Osiris Therapeutics Inc, H2 2016
  • Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H2 2016
  • Wounds - Pipeline by Pharmaxis Ltd, H2 2016
  • Wounds - Pipeline by ProMetic Life Sciences Inc, H2 2016
  • Wounds - Pipeline by RiverTown Therapeutics Inc, H2 2016
  • Wounds - Pipeline by RMB-Research GmbH, H2 2016
  • Wounds - Pipeline by RXi Pharmaceuticals Corp, H2 2016
  • Wounds - Pipeline by Sinclair Pharma Plc, H2 2016
  • Wounds - Pipeline by SomaGenics Inc, H2 2016
  • Wounds - Pipeline by Stratatech Corp, H2 2016
  • Wounds - Pipeline by TGV-Laboratories, H2 2016
  • Wounds - Pipeline by Thesan Pharmaceuticals Inc, H2 2016
  • Wounds - Pipeline by Topadur Pharma AG, H2 2016
  • Wounds - Pipeline by Trophogen Inc, H2 2016
  • Wounds - Pipeline by Tumorend LLC, H2 2016
  • Wounds - Pipeline by VBS Pharmaceuticals, H2 2016
  • Wounds - Pipeline by viDA Therapeutics Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Wounds - Dormant Projects, H2 2016
  • Wounds - Dormant Projects (Contd..1), H2 2016
  • Wounds - Dormant Projects (Contd..2), H2 2016
  • Wounds - Dormant Projects (Contd..3), H2 2016
  • Wounds - Dormant Projects (Contd..4), H2 2016
  • Wounds - Dormant Projects (Contd..5), H2 2016
  • Wounds - Dormant Projects (Contd..6), H2 2016
  • Wounds - Dormant Projects (Contd..7), H2 2016
  • Wounds - Dormant Projects (Contd..8), H2 2016
  • Wounds - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Wounds, H2 2016
  • Number of Products under Development for Wounds - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top